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Abstract
Background: Nogo-A and its putative receptor NgR are considered to be among the inhibitors of axonal regeneration
in the CNS. However, few studies so far have addressed the issue of local NgR complex multilateral localization within
inflammation in an MS mouse model of autoimmune demyelination.
Methods: Chronic experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice. Analyses were
performed on acute (days 18–22) and chronic (day 50) time points and compared to controls. The temporal and spatial
expression of the Nogo receptor complex (NgR and coreceptors) was studied at the spinal cord using epifluorescent
and confocal microscopy or real-time PCR. Data are expressed as cells/mm2, as mean % ± SEM, or as arbitrary units of
integrated density.
Results: Animals developed a moderate to severe EAE without mortality, followed by a progressive, chronic clinical
course. NgR complex spatial expression varied during the main time points of EAE. NgR with coreceptors LINGO-1 and
TROY was increased in the spinal cord in the acute phase whereas LINGO-1 and p75 signal seemed to be dominant in
the chronic phase, respectively. NgR was detected on gray matter NeuN+ neurons of the spinal cord, within the white
matter inflammatory foci (14.2 ± 4.3 % NgR+ inflammatory cells), and found to be colocalized with GAP-43+ axonal
growth cones while no β-TubIII+, SMI-32+, or APP+ axons were found as NgR+. Among the NgR+ inflammatory cells, 75.
6 ± 9.0 % were microglial/macrophages (lectin+), 49.6 ± 14.2 % expressed CD68 (phagocytic ED1+ cells), and no cells
were Mac-3+. Of these macrophages/monocytes, only Arginase-1+/NgR+ but not iNOS+/NgR+ were present in lesions
both in acute and chronic phases.
Conclusions: Our data describe in detail the expression of the Nogo receptor complex within the autoimmune
inflammatory foci and suggest a possible immune action for NgR apart from the established inhibitory one on axonal
growth. Its expression by inflammatory macrophages/monocytes could signify a possible role of these cells on axonal
guidance and clearance of the lesioned area during inflammatory demyelination.
Keywords: Nogo receptor complex, NgR, LINGO-1, p75, TROY, Experimental autoimmune encephalomyelitis,
Neuroinflammation, Macrophages
* Correspondence: symeon@med.auth.gr
4Department of Experimental Physiology, Faculty of Medicine, Aristotle
University of Thessaloniki, 546 36 Thessaloniki, Central Macedonia, Greece
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Theotokis et al. Journal of Neuroinflammation  (2016) 13:265 
DOI 10.1186/s12974-016-0730-4
Background
Numerous studies indicate the dynamic and high potential
role of neurite outgrowth inhibitor Nogo-A to inhibit,
guide, and modulate the injured and demyelinating tissue
in various models of disease. These characteristics are
dependent on the presence of Nogo-66 receptor (NgR) [1]
as well as the subcellular coreceptor components p75 [2],
TROY [3], and adaptor molecule LINGO-1 [4], compris-
ing the receptor complex that mediates myelin’s inhibitory
action. The latest finding as a component of this complex
is AMIGO3, substituting LINGO-1 under specific circum-
stances [5].
NgR is expressed by various glial and neuronal cell bodies
or axons except oligodendrocytes, which express its ligand
Nogo-A [6, 7]. This specific ligand-receptor localization has
been accounted for a neurite outgrowth inhibitory mechan-
ism, exerting a growth cone collapse effect in response to at
least two more myelin proteins, namely MAG [8] and
OMgp [9]. The 473-amino acid NgR protein is a glycosyl-
phosphatidylinositol (GPI)-linked molecule linked to an
eight-leucine-rich-repeat (LRR) domain by an LRR
carboxy-terminal (LRRCT) domain. It can be found in
three isoforms: NgR1, NgR2, and NgR3 [10], with NgR1
being the most common and best correlated to Nogo-A
[11]. The other three molecules of the NgR complex,
namely p75, TROY, and LINGO-1, are membrane corecep-
tors that regulate the downstream effects of NgR depending
on their interactions [12, 13].
The value of the Nogo-NgR pathway for control of
axonal regeneration is verified by the development of
Nogo-A and LINGO-1 monoclonal antibodies for clin-
ical trials [14, 15]. Despite the fact that NgR is key to the
pathway activation, only few studies analyzing knockout
mice in experimental autoimmune encephalomyelitis
(EAE) [16, 17] and few small interference RNA (siRNA)
experiments have been carried out in demyelination of
optic nerve tracts [18, 19], rendering its precise function
still enigmatic. In vitro experiments by Takahashi and
colleagues [20] and later further progressed by David
and colleagues [21, 22] suggest that the presence of NgR
in macrophages—apart from neurons or glia—could
support the clearance of debris and could confine the
injury away from the normal-appearing white matter
tissue. However, the question of whether the NgR com-
plex positively or negatively regulates the inflammation
spreading in a central nervous system (CNS)-based auto-
immune disease remains largely unknown so far.
The purpose of this study was to describe the spatiotem-
poral kinetics of NgR within the inflammatory sites of
experimental autoimmune demyelination, in order to
understand its roles in the inflammatory milieu. We fo-
cused on both NgR and coreceptor molecules LINGO-1,
p75, and TROY, in an attempt to characterize the Nogo-A/
NgR pathway in the autoimmune inflammatory foci. Based
on our present and previous published data [23], we
propose that NgR may have an additional role in the dis-
ease progression—besides the attributed axonal inhibition-,
namely confining the inflammatory reaction and/or the
sprouting of axons in EAE lesions.
Methods
Animal handling
Female C57BL/6 mice (n = 40), 8–10 weeks old, were
purchased from the Hellenic Pasteur Institute (Athens,
Greece) and housed in the pathogen-free animal facility
of the B’ Neurology Department, AHEPA University
Hospital, Thessaloniki, Greece. Animals were fed a nor-
mal diet and given ad libitum water without antibiotics.
All experimental procedures were conducted according
to the institutional guidelines, in compliance with the
Greek Regulations and the European Communities
Council Directive of November 24, 1986 (86/609/EEC).
Experimentation received approval from the Veterinary
Medicines Directorate (license number 177867/1510).
EAE induction and clinical evaluation
Chronic EAE was induced in animals (n = 30), with sub-
cutaneous injection of 300 μg of myelin oligodendrocyte
glycoprotein 35–55 peptide (MOG35–55) as previously
described [23, 24]. Animals inoculated with complete
Freund’s adjuvant (CFA, supplemented with 4 % mycobac-
terium tuberculosis) only did not develop lesions in the
CNS and served as controls (n = 10). All animals were
examined daily using a 6-grade scale: 0, asymptomatic; 1,
partial loss of tail tonicity; 2, flaccid tail paralysis; 3, diffi-
culty to roll over from a supine position; 4, hind limb
paralysis; 5, forelimb paresis; and 6, death due to EAE.
The following indexes were calculated based on their
daily scores: mean maximal score (MMS), area under
the curve (AUC), day of disease onset (dDO), clinical
score at day 50 (d50 score), and demyelination extent in
the spinal cord.
Tissue collection
Animals were humanely euthanized and prepared
accordingly for neuropathology and further processing.
Animals for immunohistochemistry were transcardially
perfused using phosphate buffer saline (PBS), followed
by ice-cold 4 % paraformaldehyde in PBS (4 % PFA) for
5 min. The brain and spinal cords were removed, post-
fixed in the corresponding fixation solution for 16–20 h
at 4 °C, and routinely processed for paraffin sectioning
at 6 μm. Animals for real-time PCR were euthanatized,
and their brains and spinal cords were removed, snap
frozen, and stored at −80 °C until further use.
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Histological stainings, immunohistochemistry, and
immunofluorescence
Six-micrometer-thick paraffin coronal spinal cord sec-
tions were stained with routinely used immunohisto-
chemical methods: Luxol fast blue (LFB) counterstained
with nuclear fast red for demyelination evaluation and
Bielschowsky silver impregnation counterstained with
hematoxylin for pervasive infiltratory burden and axonal
loss, as previously described [25–27]. Lectin and DAB-
based anti-Iba-1 (rabbit, WAKO) protocols were used
for microglia evaluation, as previously described [27].
Localization and neuropathological study of NgR was
performed with double immunofluorescence (dIF) also on
6-μm coronal sections. Briefly, following hydration and
incubation of the sections with 10 % fetal bovine serum
(FBS) for 30 min, primary antibodies were applied over-
night. Neuronal and glial components were evaluated for
the presence of NgR with a combination of primary
antibodies, anti-NgR (rabbit, Santa Cruz) with anti-NeuN
(mouse, Millipore) for neurons, anti-GFAP (mouse,
DAKO) for astrocytes, anti-Nogo-A (goat, Santa Cruz) for
mature oligodendrocytes, anti-Mac-3 (rat, BD Biosciences)
for detection of peritoneal/tissue macrophages and
dendritic cells, and anti-ED1 (mouse, Serotec) for detec-
tion of macrosialin (macrophages; human CD68), while
anti-Arginase-1 (goat, Santa Cruz) and anti-iNOS (mouse,
Santa Cruz) were used to distinguish M2 microglia from
the M1 phenotype [28].
Additionally, axonal epitopes were designated with the
following: anti-β-TubIII (mouse, BD Biosciences) and
non-phosphorylated neurofilament H anti-SMI-32
(mouse, Calbiochem) were used for detection of physio-
logical and pathological neuronal axons, and anti-β-
amyloid precursor protein (APP) (mouse, Millipore) and
anti-GAP-43 (mouse, Sigma) were used for axonal focal
degeneracy and regeneration, respectively. Coreceptors
LINGO-1 (rabbit, Abcam ab23631, 1:300), TROY (goat,
Santa Cruz 13711, 1:100), and p75 (mouse, Abcam
ab8877, 1:400) were also accessed and combined accord-
ingly. For specificity and quality control of the corecep-
tor antibodies, a preabsorption protocol previously
described [29] and the use of a second antibody recog-
nizing a different epitope were applied upon availability
and whenever applicable (see Additional file 1: Figure
S1). Briefly, the peptide for each preabsorption assay was
mixed with the antibody in a 10× molecular ratio and
was incubated under gentle agitation at room
temperature for 30 min. The mixture was then used in
place of the primary antibody for the rest of the IF
protocol.
Depending on the primary antibodies used, the following
secondary fluorescent antibodies were used at the spectrum
of green (488, Biotium; Alexa Fluor) and red (555-568,
Biotium; Alexa Fluor) for the rest of the markers. Sections
were mounted with 4′,6-diamidino-2-phenylindole (DAPI)
(Biotium).
Neuropathology evaluation
Pathologic examination of demyelination, axonopathy, in-
flammation, and microglia/macrophages was performed
under a Zeiss Axioplan 2 light microscope by two, blinded
to the experimental groups, investigators. Photos were
captured with the aid of a CCD camera (Nikon), and ana-
lysis of the designated areas was performed with ImageJ
software.
Demyelination was evaluated on approximately 15
Luxol fast blue-stained sections. Demyelinated areas and
the total area of white matter were carefully circum-
scribed and expressed as a percentage (demyelinated/
total wm area), as previously described [23]. Axonal loss
was assessed on approximately ten randomly selected
silver-stained spinal cord sections within 150 × 150-μm
areas from the three major spinal cord white matter col-
umns (ventral, lateral, and dorsal), spaced at least 60 μm
apart, and graded as 0 = normal/even silver stain
throughout the white matter compared to unimmunized
mice; 1 = small spurious areas in the white matter that
lack silver stain; 2 = small, but frequent, areas in the
white matter that lack silver stain; and 3 = extensive loss
of silver stain throughout the white matter, as previously
described [25]. Typical images of scores 0–3 are pre-
sented in Additional file 1: Figure S1.
For the evaluation of inflammation, hematoxylin-stained
fields of the same sections were examined for each animal,
using a prefrontal microscope grid. Microglia/macro-
phagic populations were assessed in respective white
matter areas with ionized calcium-binding adaptor
molecule-1 (Iba-1) staining. The number of perivascular
infiltrates and microglia/macrophages were counted and
presented as cells/mm2.
NgR profile assessment
Spatial analysis for NgR protein was performed in the cen-
ter of six to eight inflammatory foci per spinal cord per
animal, spaced at least 50 μm apart. Sections were studied
using confocal microscopy (Nikon C1-Eclipse TE-2000U)
under ×60 optical fields. Briefly, images were captured,
within a predefined 305 × 305-μm area, and the NgR-
positive signal was evaluated for levels of coexpression
with miscellaneous markers. GAP-43 and APP signal was
measured as an integrated density (IntDen) as previously
described [23], using the ImageJ software. Colocalization
percentages were also estimated, wherever applicable.
NgR coreceptor real-time PCR
Molecular analysis of coreceptors LINGO-1, TROY, and
p75 was performed with real-time PCR in spinal cord
extracts based on a protocol previously described [23].
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Briefly, total RNAs were extracted from spinal cord tissues
using Trizol reagent (Invitrogen); RNA was reverse tran-
scribed to complementary DNA (cDNA) with iScript
cDNA Synthesis Kit (BioRad), and real-time PCR was per-
formed using BioRad IQ5 ICycler Multicolor Detection
System. The relative gene expression was normalized to β-
actin which served as an internal control. Additionally,
GAPDH was used as a second, quality control, house-
keeping gene. Primer sequences for SYBR Green probes
of target genes are as follows: LINGO-1 (Lingo1): forward
5′ CATCAGGTGAGCGAGAGGAT 3′ and reverse 5′
CGTCCTGGTTGAGTGTCTTG 3′ giving rise to a 267-b
p product; p75 (Ngfr): forward 5′ CTGCTGCTTCT
AGGGGTGTC 3′ and reverse 5′ ACACAGGGAGCGG
ACATACT 3′ giving rise to a 248-bp product; TROY
(Tnfrsf19): forward 5′ AGATTGCAGGCAGCAGGA 3′
and reverse 5′ TCCGCACATGGCTTACACTT 3′ giving
rise to a 186-bp product; β-actin (Actb): forward 5′
TTGTAACCAACTGGGACGATATGC 3′ and reverse 5′
GATCTTGATCTTCATGATGCTAGG 3′ giving rise to a
139-bp product; and GAPDH (Gapdh): forward 5′ GG
ATGCAGGGATGATGTTCT 3′ and reverse 5′ AAG
GGCTCATGACCACAGTC 3′ giving rise to a 116-bp
product. The results were analyzed using ΔΔCt method.
Statistical analysis
All data are given as mean ± standard error of the mean
(SEM). For statistical analysis, the SPSS Statistics 18
package was used. Student’s t test and one-way analysis
of variance (ANOVA) with Dunnett’s and Bonferroni
post hoc tests were used for comparisons of two or more
groups, respectively. Non-parametric data were com-
pared using Mann-Whitney U test. Semi-quantitative
data were analyzed using the Pearson χ2 test or Fisher’s
exact test, where appropriate, and the ordinal data were
displayed as bar graphs. Two-tailed values of p < 0.05
were considered statistically significant for all tests.
Results
Clinical course and inflammatory pathology
MOG-inoculated animals developed a typical chronic
MOG-EAE pattern (Fig. 1A) with MMS = 3.76 ± 0.28,
AUC = 85.89 ± 11.73, dDO = 14.50 ± 0.47, and d50
score = 2.06 ± 0.44. Percentage of demyelination of the
spinal cord was found 22.20 ± 1.89 % and 14.80 ±
1.34 % (p < 0.01) during the acute and chronic phases,
respectively (Fig. 1B). Control animals (CFA inoculated
animals) did not develop EAE.
Tissue sections from acute and chronic phases were
compared to control animals. Hematoxylin staining
revealed perivascular infiltrates (cells/mm2) within the
white matter of the spinal cord in the acute phase
(123.90 ± 9.89 cells/mm2) that was reduced during the
chronic phase (87.80 ± 6.85 cells/mm2; p < 0.01) (Fig. 1C,
F1–H2). Axonal loss assessed by Bielschowsky staining
was found semi-quantitatively more extensive in the
chronic phase than the acute (p < 0.05) and control group
(p < 0.001), respectively (Fig. 1D, F1–H2). Microglial/mac-
rophagic populations were increased in the acute phase
(101.40 ± 4.63 cells/mm2 from control animal levels 10.44
± 2.45 cells/mm2; p < 0.001) and then decreased towards
the chronic phase (83.67 ± 5.77 cells/mm2; p < 0.05 versus
acute and p < 0.001 versus controls) (Fig. 1E, I1–K2).
Pattern of NgR expression inside and peripherally to EAE
lesions of the spinal cord
In the spinal cord of controls, the highest NgR signal
was obtained from neurons of the gray matter (>80 % of
the total signal) and the rest from axonal elements
(DAPI-negative structures).
In the acute phase, neuronal NgR signal (Fig. 2A) was de-
creased compared to controls (15.85 ± 9.09 % NeuN+NgR+
double-positive cells from 82.37 ± 7.81 % of controls; p <
0.001), was absent from astrocytes and oligodendrocytes
(Fig. 2B, C), and found to be highly expressed in the
lesioned white matter (306.7 ± 32.06 cells/mm2, 75.6 ±
9.04 % lectin+NgR+ inflammatory cell double positive)
(Fig. 2D). NgR was found to be expressed in specific micro-
glial/macrophagic cells; 49.6 ± 9.5 % were ED1+ (Fig. 2F),
but Mac-3 negative (Fig. 2E), while the remaining per-
centage (~10 % the total signal) was found in axonal
structures and specifically only in regenerative growth
cones (GAP-43+ structures, Fig. 2I) and nowhere else
throughout the axon (β-TubIII and SMI-32 negative,
Fig. 2G, H). On the contrary, this specific localization
was not observed in control animals.
In the chronic phase, the inflammatory process de-
clines with a diminished appearance of inflammatory
cells resulting in a decreased detection of cellular NgR
localization within residual inflammations (<20 % of the
total signal) while increasing the axonal localization in
growth cones (IntDen, 195.975 ± 33.931) alongside a
similar increase, 2.5-fold (39.44 ± 8.61 cells/mm2 versus
acute 15.85 ± 9.09 cells/mm2; p < 0.01) in neurons of the
gray matter of the spinal cord. NgR localization in each
phase is shown graphically in Fig. 2J.
Analysis of LINGO-1, p75, and TROY mRNA expression in
the spinal cord by real-time PCR
The messenger RNA (mRNA) levels of the NgR corecep-
tors were found to fluctuate, depending on the stage
studied. Expression of LINGO-1 in the spinal cord was
increased in the acute phase compared to controls and
followed a statistically significant increase in the chronic
phase (p < 0.001 compared to controls) (Fig. 3A). The
corresponding normalized expression of p75 showed a
decrease during the acute phase but increased signifi-
cantly in the chronic phase (p < 0.001 compared to the
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Fig. 1 (See legend on next page.)
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acute phase) (Fig. 3B). On the contrary, TROY levels in the
spinal cord appeared elevated only in the acute phase (p <
0.05 compared to controls and p < 0.01 compared to the
chronic phase) and returned to the levels of controls in the
chronic phase (Fig. 3C). Results were verified by the quality
control, GAPDH analysis (Additional file 1: Figure S1).
LINGO-1, p75, and TROY expression and cellular localization
in the spinal cord
The protein expression of the NgR coreceptors exhibited
a temporal profile in accordance with their respective
mRNA expression levels. In controls, LINGO-1 was
mostly expressed in motor neuronal bodies of the spinal
cord while coreceptors p75 and TROY were almost neg-
ligible both in the gray and white matter of the spinal
cord (Fig. 4A–C). Their expression fluctuated, like that
of NgR, mainly within the inflammatory foci (Fig. 4D),
depending on the phase studied.
The expression of LINGO-1 was increased in the peri-
vascular inflammatory foci during the chronic phase
(467.8 ± 48.18 cells/mm2; Fig. 4E1) while a similar increase
was detected in axonal structures (IntDen, 249.156 ±
26.177; Fig. 4H1). LINGO-1 was found to be colocalized
with both NgR (90.25 ± 5.36 % coexpression) and TROY
(87.80 ± 7.15 % coexpression) in the acute phase while a
corresponding colocalization was found between NgR
(88.91 ± 7.50 % coexpression) and p75 (86.32 ± 9.29 %
coexpression) in the chronic phase. Double immunofluor-
escence also revealed that the majority (91.42 ± 4.88 %) of
ED1+ cells coexpressed LINGO-1 in the acute phase and
an equal, high ratio of GAP-43+ axonal structures (90.71 ±
5.63 %) coexpressed LINGO-1 in the chronic phase.
Expression of p75 was increased only in the residual
inflammatory foci of the chronic phase (IntDen 121.521 ±
15.709, versus acute 15.375 ± 1.399 and controls 2.650 ±
0.245; p < 0.001 for all comparisons) to axonal structures
(Fig. 4G2, H2, D2, E2, A2, B2). On the other hand, expres-
sion of TROY was restricted within inflammatory cells at
the lesion sites of the acute phase (106.7 ± 9.57 cells/mm2
versus chronic 15.56 ± 3.76 cells/mm2 and controls 1.48 ±
0.34; p < 0.001 for all comparisons) (Fig. 4F2, I2, C2).
Coreceptor % levels in each phase are shown graphically
in Fig. 4J. Taken together, these data suggest LINGO-1
and TROY as mainly acute-phase responders, expressed
by the macrophages/microglia, while p75 is complementa-
rily expressed in growth cones during the chronic phase.
NgR expression in correlation with axonal regeneration
and pathology
The increase of GAP-43 in the lesioned areas of the acute
phase coincides widely with the increase of NgR signal
(IntDen 350.255 ± 60.395) (Fig. 5A, E), in contrast to the
adjacent normal-appearing white matter and compared to
controls (29.731 ± 1.878; p < 0,001). These data are in
accordance with our previously published data for Nogo-A
[23]. The coexpression rate was up to 85.09 ± 3.57 %. The
same pattern was observed in the chronic phase to a lesser
extent since the two marker intensities exhibited an
equivalent twofold decrease (195.975 ± 33.931) (Fig. 5B, E).
The coexpression rate was also high and equal to 89.82 ±
2.3 %. In contrast, NgR failed to be found colocalized with
APP, neither in the acute nor in the chronic phase of the
disease (Fig. 5C, D, F).
NgR macrophagic/microglial phenotype
The control group did not express any Arginase-1
or iNOS in the white matter of the spinal cord,
inducers for M2 and M1 cell polarization, respectively.
Arginase-1 was expressed twofold higher in the acute
phase (51.33 ± 7.38 cells/mm2) compared to iNOS
(21.11 ± 2.07 cells/mm2) and revealed a high degree of
colocalization (86.03 ± 2.08 %) within NgR+ cells
(Fig. 6A). NgR+ M2-type inflammatory cells were
57.94 ± 3.07 % within the inflammatory foci of the
acute phase (Fig. 6B). On the contrary, iNOS+ macro-
phages/microglia did not coexpress NgR and were only
found in close proximity to NgR+ cells (Fig. 6C). Levels
of Arginase-1 and iNOS remained unchanged in the
subsequent chronic phase. NgR+ M2-type cells were
49.68 ± 3.22 % within the residual inflammatory foci of
the chronic phase (Fig. 6B) whereas an M1 ratio could
not be calculated. These data suggest an interesting
(See figure on previous page.)
Fig. 1 Clinical course, demyelination, infiltratory, axonal, and microglial status in the spinal cord of EAE animals. A Graphic depicts the EAE course
and the two main time points analyzed. B % demyelination as resulted by LFB staining. On the chronic phase, demyelination was significantly lower
compared to the acute phase (p< 0.01). Infiltratory burden (C) expressed as cells/mm2 and axonal loss (D) measured semi-quantitatively (0 = normal/even
silver stain throughout the white matter; 1 = small spurious areas in the white matter that lack silver stain; 2 = small, but frequent, areas in the white matter
that lack silver stain; and 3 = extensive loss of silver stain throughout the white matter) were computed from the same sections of a modified Bielschowsky
protocol counterstained with hematoxylin (panels F2, G2, H2, and their corresponding field magnifications F1, G1, and H1). Perivascular
infiltrations were significantly higher in the acute phase compared to chronic (p < 0.01) while axonal loss was found higher in the chronic
phase compared to acute (p < 0.05). Panels I2, J2, and K2 show the adjacent sections of the spinal cord stained for microglia/macrophages
(Iba-1+; panels I1, J1, and K1 show corresponding field magnifications). Microglia (E, cells/mm2) differed significantly between control and
EAE animals (p < 0.001 and p < 0.05 for acute and chronic phases, respectively). Error bars indicate the standard statistical error of the mean
(SEM), #p < 0.001 (versus controls), **p < 0.01, *p < 0.05. Scale bar = 100 μm
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link between NgR receptor and the neurorestorative
M2 phenotype of macrophages/microglia in EAE, fur-
ther implying a possible role of this molecule in the
repairing process.
Discussion
The main finding of our present study is the phase-
sensitive differential expression of the NgR complex in
the neurodegenerative inflammatory environment of
Fig. 2 Cellular and axonal localization of the NgR protein in the acute phase of EAE. Neuronal expression (A) was acquired from the motor
neurons of the gray matter, while the protein was absent from astrocytes (B) and oligodendrocytes (C) of the adjacent lesioned white matter. The
macrophagical expression was restricted to subpopulations of microglia/macrophages as shown by the lectin staining (D) in activated ED1-positive
macrophages and absent from Mac-3-positive macrophages (E, F). Axonal NgR was even more restricted, and while it was absent from the main
axonal tract (G) or damaged sites, positive for non-phosphorylated form of neurofilament SMI-32 (H), it was detected at regenerative GAP-43+ axonal
growth cones (I). Inserts C, F1, F2, I1, and I2 represent z-stack scans 20 steps (0.3 μm) made in sections of 6 μm. C shows the contact point of two cells
while F1, F2, I1, and I2 coexpression is shown on two different channels of the respective pseudocolor. Arrowheads indicate the NgR+ cells, and arrows
indicate the negative NgR structures. J NgR % levels and its subcellular façade in controls, acute phase, and chronic phase of EAE. Scale = 10 μm
Theotokis et al. Journal of Neuroinflammation  (2016) 13:265 Page 7 of 13
MOG-EAE. Our data indicate that NgR is expressed in
motor neurons of the gray matter, regenerating axonal
growth cones and the M2 microglial/macrophages.
Surprisingly, we show for the first time that this ex-
pression of NgR on microglia/macrophages is selective
for Arginase-1+ M2 microglia/macrophages. In agree-
ment with the NgR localization, we showed that both
mRNA and protein of coreceptor LINGO-1 exhibit the
same pattern in the spinal cord of EAE animals. Fur-
thermore, molecular and histological findings of p75
and TROY coreceptors revealed that their expression is
complementary between acute and chronic phases,
respectively.
The EAE course involves different phases of inflam-
mation and axonal pathology in the spinal cord [27].
Previously, we established that the mRNA and protein
levels of NgR along with its putative ligand, Nogo-A,
are subjected to changes under this inflammatory de-
myelination of the CNS, showing a notable increase
during the chronic phase of EAE [23]. Because of the
high local heterogeneity of NgR expression, further
studies were required in order to decode more refined
actions within the spinal cord. In this study, we initially
showed that NgR was predominately expressed in
motor neurons of the spinal cord gray matter of control
animals (>80 %). In vitro data have previously con-
nected NgR’s neuronal presence to growth cone col-
lapse following injury [1, 8, 30]. However, the spatial
expression changed drastically during the main time
points of EAE and seemed to shift in terms of cellular
localization.
In the acute phase, we showed that the majority of the
NgR protein signal (70–75 %) was detected in inflammatory
cells of lesioned areas, while lesser signal was acquired from
axonal elements of white matter (~10–15 %). Although B
and T cell populations were not examined in this study, it
has been previously published that NgR deficiency does not
affect the immune cell repertoire [16] nor the clinical out-
come of EAE [17]. On the other hand, NgR has been
strongly connected to cell adhesion [31, 32], motility of
microglia and its regulation [22, 33, 34]. Thus, specific
markers were selected for each developmental stage of
microglia/macrophages; lectin staining was applied for the
identification of resting and activated microglia, Mac-3 to
detect blood-borne macrophages, and CD68 (ED1) to label
the phagocytic cells [6, 22]. Our data show that during the
acute phase, NgR was highly expressed by ED1+ cells, re-
vealing the connection of an outgrowth regulator to one of
the key players of inflammatory regulation in EAE [35].
NgR’s microglial localization in microglia has also been
studied in traumatic brain injury (TBI) [36], linking the
molecule to developmental functions and aging.
During the chronic phase, the percentage of axonal
localization increased to 40–45 % and neuronal to 30–
40 % while the microglial/macrophage expression was
dramatically reduced to <20 %. The latest reduction
might be due to the less inflammatory burden of the
phase, while the neuronal reappearance might be con-
nected to axonal remodeling and plasticity of corticosp-
inal tract found during EAE rehabilitation period [37].
Although we failed to detect NgR on normal (β-TubIII)
or pathological (SMI-32) axonal tracts, a significant
colocalization with GAP-43 was seen on regenerative
axonal growth cones. Such result further strengthens
our previous Nogo-A findings, establishing that inter-
action of Nogo-A and NgR in the different phases of the
EAE course plays a significant role in disease progres-
sion, accounting for inhibition of neurite outgrowth [23].
Real-time PCR molecular analysis in conjunction with
dIF tissue stainings of serial sections revealed the kinetics
of NgR coreceptors. LINGO-1 followed NgR’s pattern mo-
tility, both level- and cell-wise. This suggests that these
two molecules are regulated together and exhibit an
activity-induced neural plasticity response, especially for
the neuronal coexpression [38]. On the other hand, p75
and TROY exhibited a more specific phase-dependent
expression. It has been reported that p75 is present in
areas where no TROY exists and vice versa [39, 40], thus
complementing their actions in order to activate the
downstream pathway of NgR [41, 42]. We found that
Fig. 3 mRNA levels of coreceptors LINGO-1, p75, and TROY in the spinal cord of EAE animals. Levels of mRNA expression in the spinal cord by
real-time PCR analysis for the coreceptors (A) LINGO-1, (B) p75, and (C) TROY, respectively. Error bars indicate the standard statistical error of the
mean (SEM), ***p < 0.001, **p < 0.01, *p < 0.05
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Fig. 4 Protein expression of NgR and coreceptors (NgR complex) in the different phases of EAE. Double-fluorescent images indicating the expression
of NgR, LINGO-1, p75, and TROY in serial spinal cord sections in controls (A–C), in the acute phase (D–F), and the chronic phase (G–I), respectively.
Inserts represent magnified areas (dashed rectangles) where the highest expression of the molecules was found. A1–C2 shows the neuronal expression
of NgR and LINGO-1 to the motor neurons of the gray matter, and there is negligible expression of p75 and TROY. D1–F2 shows the macrophage
expression of NgR, LINGO-1, and TROY around the inflammatory infiltrates of the white matter, and there is the complete absence of p75. G1–I2 shows
the axonal expression of NgR, LINGO-1, and p75, which was present in DAPI-negative structures, while there is negligible expression of TROY in the
residual inflammatory infiltrates. The arrow in F2 represents enlarged TROY+ cell insert. J LINGO-1, p75, and TROY % levels with their subcellular façade
in different phases of EAE. Scale = 100 μm
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more than 25 % of macrophages of the acute phase were
found to express TROY in their cytoplasm while no p75
was found. TROY protein has been found up-regulated in
MS brain lesions [43]. The absence of p75 in TROY+ cells
has been also observed in sciatic nerve (PNS) of rats after
injury [22]. Conversely, in the chronic phase, the appear-
ance of p75 in no DAPI-correlated structures appeared to
be unaffected by the lack of TROY from residual macro-
phages. Furthermore, neither of two proteins appeared in
controls, leading us to assume that this spatiotemporal
rearrangement of the molecules at a systematic level is
associated with the processes occurring in the various
stages of EAE, seen under certain circumstances [42, 44,
45]. The significance of these findings would be increased
by functional experiments (KO mice or blocking peptides
for LINGO-1, p75, and TROY), which unfortunately are
not feasible for the time being, establishing a weakness in
this study.
In order to understand the possible role of NgR in the
inflammatory processes, we correlated its expression with
microglia/macrophage polarization [28, 46]. Our data
showed that NgR is expressed only by M2 macrophages/
Fig. 5 NgR protein expression in correlation with axonal regeneration and degeneration markers. Double-fluorescent immunostaining of NgR
with molecular markers GAP-43 (A, B) and APP (C, D), respectively. E The data is displayed as integrated density (in arbitrary units) GAP-43, APP,
and NgR in controls, acute phase, and chronic phase. F Percentage of GAP-43+ or APP+ axons coexpressing NgR. *** and # denote p < 0.001 for
comparison of the acute and chronic phases, respectively, compared to controls, ‡p < 0.001 for comparisons indicated on the bars. ns non significant
comparison. Scale = 20 μm
Fig. 6 M1–M2 phenotype of NgR+ macrophagic/microglial populations within the inflammatory foci of the spinal cord. A A high expression of
the Arginase-1 marker was observed in NgR+ cells (juxtapositions of separate color channels in A1–A3) within the acute lesions in the white matter. B
Levels did not differ significantly in the chronic phase. C No connection (coexpression) was observed for iNOS+ (arrows) and NgR+ (arrowheads) cells in
both acute and chronic phases. ***p < 0.001, ns non significant comparison. Scale = 20 μm
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microglia suggesting that it may have an important but un-
known role so far for their functions [46, 47]. Previous
studies on rat EAE lesions support a positive role of the
inflammatory ED1+ macrophages for the promotion of the
repair process and recovery [28]. Additionally, the role of
M2 microglia has been proven beneficial in EAE, by creat-
ing an anti-inflammatory environment, accompanied by
tissue repair [46]. As a de novo synthesis of NgR in macro-
phages is possible, as seen after sciatic nerve crush in rats
[21, 22], it may further prevent the spread of inflammation
in the adjacent normal-appearing white matter [22]. Taken
together, along with the high ratio of ED1+ macrophages
present within the inflammatory foci, we propose that those
phagocytic Arginase-1+NgR+ cells contribute to inflamma-
tory regulation facilitating the repair process in the tissue.
In conclusion, we provide descriptive evidence for a pos-
sible action of NgR within inflammatory lesions of EAE
acute and chronic phases. We show that NgR, LINGO-1,
and TROY are expressed by macrophages of the acute
phase and that NgR is also expressed on GAP-43+ axonal
growth cones. Interestingly, the majority of NgR+ macro-
phages present in the inflammatory foci acquire the anti-
inflammatory M2 phenotype which might ultimately lead
to area clearance. As the kinetics of NgR, LINGO-1, p75,
and TROY are tightly regulated and interchange both
cellularly and time-wise, we propose that this system might
be involved in the regulation, resolution, and repairing
local processes after the inflammatory axonal injury in the
spinal cord of EAE animals.
Conclusions
This study demonstrates the expression kinetics of the
Nogo receptor complex in autoimmune demyelinating
lesions of EAE. Our data supports a phase-driven differen-
tial expression of all the molecules of the complex with a
distinct temporal profile pattern, thereby defined by the
EAE course. We further provide a possible underlying
mechanism based on the selective expression milieu of
NgR in GAP-43+ axonal growth cones and its coexpres-
sion in Arginase-1+, M2 phenotype alternatively activated
macrophages.
Additional file
Additional file 1: Figure S1. Bielschowsky staining, immunofluorescence,
and real-time PCR quality controls. (A1–4) Typical images of scores 0–3 in
Bielschowsky silver staining. (B, C) Preabsorption assay for LINGO-1 and TROY
in serial sections of chronic and acute phases, respectively (the phase
where signal is most abundant). (B1) LINGO-1 antibody specifications:
rabbit polyclonal, Abcam ab23631, LOT N/A, dilution 1:300. (B2) LINGO-1
peptide specifications: rabbit, Abcam ab25890, LOT #GR41007-1, incubation
with ab in 10× molecular ratio. (C1) TROY antibody specifications: goat
polyclonal, Santa Cruz sc-13711 (E-19), LOT #H0707, epitope mapping near
the C-terminus of TROY of mouse origin, dilution 1:100. (C2) TROY peptide
specifications: goat, Santa Cruz sc-13711 P, LOT #B0402, incubation with ab
in 10× molecular ratio. (D, E) Antibody specificity test for p75 and NgR with
the use of another antibody (different company) recognizing a different
epitope in serial sections of chronic and acute phases, respectively (the
phase where signal is most abundant). (D1) p75 antibody #1 specifications:
mouse monoclonal, Abcam ab8877, LOT GR136825-1, ME20.4, dilution
1:400. (D2) p75 antibody #2 specifications: mouse monoclonal, Santa Cruz
p75 (B-1) sc-271708, LOT #J0611, epitope mapping between amino acids
393–427 at the C-terminus of NGFR p75 of human origin, 1:100. (E1) NgR
antibody #1 specifications: rabbit polyclonal, Santa Cruz sc-25659 (H-120),
LOT E1209, epitope corresponding to amino acids 31–150 mapping near
the N-terminus of Nogo-R of human origin, dilution 1:100. (E2) NgR
antibody #2 specifications: rabbit polyclonal, Abcam ab26291, LOT N/A,
epitope from within residues 150–250 of rat Nogo receptor, dilution 1:100.
(F) β-actin real-time PCR quality control showing the specific amplification
products on agarose gel and the melting curves of their respective genes;
curve identifier: light green TROY, orange p75, dark green LINGO-1. (G)
mRNA levels of coreceptors LINGO-1, p75, and TROY in the spinal cord of
EAE animals by real-time PCR analysis using GAPDH as a second, quality
control, house-keeping gene. The levels of mRNA expression for the
coreceptors (G1) LINGO-1, (G2) p75, and (G3) TROY, followed the same
pattern with those that underwent β-actin analysis. Error bars indicate the
standard statistical error of the mean (SEM), ***p < 0.001, **p < 0.01. Black
scale bar = 20 μm.
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